Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease-Reference-Cited by-同舟云学术

Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease

Published:2017-10 Issue:4 Volume:92 Page:922-933
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Hwang Vicki J.,Zhou Xia,Chen Xiaonan,Trott Josephine,Abu Aboud Omran,Shim Kyuhwan,Dionne Lai Kuan,Chmiel Kenneth J.,Senapedis William,Baloglu Erkan,Mahjoub Moe R.,Li Xiaogang,Weiss Robert H.

Publisher

Elsevier BV

Subject

Nephrology

Reference44 articles.

1. Autosomal dominant polycystic kidney disease;Gabow;N Engl J Med,1993

2. Autosomal dominant polycystic kidney disease;Torres;Lancet,2007

3. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease;Gabow;Kidney Int,1992

4. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate;Hwang;Am J Physiol Renal Physiol,2015

5. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy;Rowe;Nat Med,2013

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death;Journal of Medicinal Chemistry;2024-04-05

2. Single-Cell and CellChat Resolution Identifies Collecting Duct Cell Subsets and Their Communications with Adjacent Cells in PKD Kidneys;Cells;2022-12-22

3. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease;American Journal of Physiology-Renal Physiology;2022-10-01

4. Machine Learning-Based Virtual Screening Strategy RevealsSome Natural Compounds as Potential PAK4 Inhibitors in Triple Negative Breast Cancer;Current Proteomics;2021-11-23

5. Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review;Expert Opinion on Therapeutic Patents;2021-08-09